VELCADE

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug VELCADE contains one active pharmaceutical ingredient (API):

1	Bortezomib UNII 69G8BD63PP - BORTEZOMIB
	Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.
	Read more about Bortezomib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Velcade 3.5 mg powder for solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
VELCADE Powder for solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XG01	Bortezomib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors
Discover more medicines within L01XG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12219D, 12227M
BR	Câmara de Regulação do Mercado de Medicamentos	514506401156317
CA	Health Products and Food Branch	02262452
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	27.605-1-03-12
EE	Ravimiamet	1148004, 1364868
ES	Centro de información online de medicamentos de la AEMPS	04274001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	017195
FR	Base de données publique des médicaments	62438913, 69756861
GB	Medicines & Healthcare Products Regulatory Agency	75131
HK	Department of Health Drug Office	60429, 63741
IL	מִשְׂרַד הַבְּרִיאוּת	4829
JP	医薬品医療機器総合機構	4291412D1024
LT	Valstybinė vaistų kontrolės tarnyba	1031151, 1032114
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	654M2004
NL	Z-Index G-Standaard, PRK	75299, 93610
NZ	Medicines and Medical Devices Safety Authority	11690, 13403
PL	Rejestru Produktów Leczniczych	100085192, 100194113
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W42249001, W53033001
SG	Health Sciences Authority	13064P
TN	Direction de la Pharmacie et du Médicament	15273011H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699593775017
US	FDA, National Drug Code	63020-049
ZA	Health Products Regulatory Authority	43/26/0427, A40/26/0005